Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

8,815 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Fazirsiran for Liver Disease Associated with Alpha1-Antitrypsin Deficiency.
Strnad P, Mandorfer M, Choudhury G, Griffiths W, Trautwein C, Loomba R, Schluep T, Chang T, Yi M, Given BD, Hamilton JC, San Martin J, Teckman JH. Strnad P, et al. Among authors: chang t. N Engl J Med. 2022 Aug 11;387(6):514-524. doi: 10.1056/NEJMoa2205416. Epub 2022 Jun 25. N Engl J Med. 2022. PMID: 35748699 Clinical Trial.
RNA interference targeting ANGPTL3 for triglyceride and cholesterol lowering: phase 1 basket trial cohorts.
Watts GF, Schwabe C, Scott R, Gladding PA, Sullivan D, Baker J, Clifton P, Hamilton J, Given B, Melquist S, Zhou R, Chang T, San Martin J, Gaudet D, Goldberg IJ, Knowles JW, Hegele RA, Ballantyne CM. Watts GF, et al. Among authors: chang t. Nat Med. 2023 Sep;29(9):2216-2223. doi: 10.1038/s41591-023-02494-2. Epub 2023 Aug 25. Nat Med. 2023. PMID: 37626170 Free PMC article. Clinical Trial.
RNA Interference Therapy Targeting Apolipoprotein C-III in Hypertriglyceridemia.
Gaudet D, Clifton P, Sullivan D, Baker J, Schwabe C, Thackwray S, Scott R, Hamilton J, Given B, Melquist S, Zhou R, Chang T, San Martin J, Watts GF, Goldberg IJ, Knowles JW, Hegele RA, Ballantyne CM. Gaudet D, et al. Among authors: chang t. NEJM Evid. 2023 Dec;2(12):EVIDoa2200325. doi: 10.1056/EVIDoa2200325. Epub 2023 Nov 17. NEJM Evid. 2023. PMID: 38320498
Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia.
Ballantyne CM, Vasas S, Azizad M, Clifton P, Rosenson RS, Chang T, Melquist S, Zhou R, Mushin M, Leeper NJ, Hellawell J, Gaudet D. Ballantyne CM, et al. Among authors: chang t. N Engl J Med. 2024 May 28. doi: 10.1056/NEJMoa2404143. Online ahead of print. N Engl J Med. 2024. PMID: 38804517
Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for Mixed Hyperlipidemia.
Rosenson RS, Gaudet D, Hegele RA, Ballantyne CM, Nicholls SJ, Lucas KJ, San Martin J, Zhou R, Muhsin M, Chang T, Hellawell J, Watts GF; ARCHES-2 Trial Team. Rosenson RS, et al. Among authors: chang t. N Engl J Med. 2024 May 29. doi: 10.1056/NEJMoa2404147. Online ahead of print. N Engl J Med. 2024. PMID: 38809174
Comparative effectiveness and tolerability of calcitonin gene-related peptide (CGRP) monoclonal antibodies and onabotulinumtoxinA in chronic migraine: A multicenter, real-world study in Taiwan.
Wang YF, Yang FC, Chen LA, Chang TY, Su HC, Yang CP, Tu YH, Tzeng YS, Chen SP, Fuh JL, Lai KL, Ling YH, Chen WT, Wang SJ. Wang YF, et al. Among authors: chang ty. Eur J Neurol. 2024 Jun 5:e16372. doi: 10.1111/ene.16372. Online ahead of print. Eur J Neurol. 2024. PMID: 38837528
Aerosol Box Use in Reducing Health Care Worker Contamination During Airway Procedures (AIRWAY) Study: Secondary Workload and Provider Outcomes in a Simulation-Based Trial.
Singer Harel D, Lin Y, Lo CY, Cheng A, Davidson J, Chang TP, Matava C, Buyck M, Neveu G, Collia N, Fayyaz J, Manshadi K, Levy A, Pellerin S, Pirie J; International Network for Simulation-based Pediatric Innovation, Research, and Education Aerosol Generating Medical Procedures (INSPIRE AGMP) Investigators. Singer Harel D, et al. Among authors: chang tp. Pediatr Crit Care Med. 2024 Jun 5. doi: 10.1097/PCC.0000000000003535. Online ahead of print. Pediatr Crit Care Med. 2024. PMID: 38836694
8,815 results